| Co-Chairs |
|
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
Director, Thoracic Oncology Program
UC Davis Cancer Center
Sacramento, CA |
|
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain |
| |
|
|
|
|
|
CME-Accredited Webcasts, PowerPoint® Slide and Audio Downloads, and
i-Tunes Podcast Downloads
All 6 presentations and 2 Q&A interactive panel discussions between faculty and audience from the live course
"Personalizing the Treatment of Solid Malignancies with Taxane-Based Therapies"
Chicago, IL, May 30, 2008
|
You may participate in any or all of the 10 sessions of enduring materials for CME credit or Certificate of Attendance after you review the required ACCME (Accreditation Council on Continuing Medical Education) information on this and the following Web pages.
|
|
Menu
|
|
Overview of This CME-Accredited Educational Activity
Your Options for Methods of Participation are:
- View and/or listen to any of the 8 sessions (listed below) via an Adobe Flash Webcast
- Download any slides as PowerPoint Presentations
- Download any audio only as MP3s or Podcasts
- Request a DVD-ROM of all 8 sessions
|
These educational enduring materials are the complete on-line, Web-based version of the “Personalizing the Treatment of Solid Malignancies with Taxane-Based Therapies” conducted May 30, 2008 in Chicago, IL.
There are 6 presentations and 2 Q&A interactive panel discussions between the faculty and audience with both clinical cases and audience questions. Each of these 8 sessions is approximately 15 minutes in length, and each will permit you to earn 0.25 hours of AMA PRA Category 1 Credits™. Sessions can be individually reviewed for credit. You can participate in as few or as many as you desire.
CME-Accredited Educational Activity Dates and Time to Complete
Date of release: July 21,2008
Date expires (CME credit will not be avaliable): July 21, 2009
Average time to complete each individual session: 15 minutes
Time to complete entire activity: 2 hours
Overview
During the past two decades the taxanes have been utilized in the treatment
of many types of cancer. Although they have demonstrated efficacy,
significant toxicities associated with taxane treatment remain. As a result,
new formulations of taxanes have been developed that may both improve
antitumor activity and reduce toxicity.
Because cancers are clinically heterogeneous, and it is generally accepted
that the different clinical courses of patients with histologically similar
tumors are due to molecular differences among cancers, detailed molecular
analysis of the cancer is believed to provide prognostic information. Recent
advances in molecular analytical techniques have led to rapid expansion of
novel diagnostics designed to personalize cancer care. Recently, biomedical
research has identified gene expression profiles which can be used
to subdivide cancer patients into subpopulations with different response
characteristics to taxanes and other chemotherapeutic agents. Much work
has gone into identifying which of these subpopulations will respond better
to taxane therapy. Additionally, the field of pharmacogenomics has made
rapid advances in understanding the relationship between patient genotype
and response to chemotherapy and this has begun to provide information
that is useful for optimizing patient treatment.
Our increased understanding of the complexity of cancer, and the pathways
that are involved, supports the emerging concept of “personalized therapy”
including combinations of therapeutic agents in the effective treatment
of cancer patients. Indeed, the development of biomarkers to identify the
pathways that play significant roles in the pathology of individual cancers
is an area of substantial effort. This symposium will discuss the use of
taxanes and their combination with other anti-cancer agents in the development
of novel treatment strategies for solid malignancies, and its future
directions.
Physician Practice Gap Summary (formerly Educational Needs Summary)
As we treat and cure more cancer our understanding of the initiation and
growth of malignancy, as well as its response to treatment also increases.
This enhanced understanding of the biology of cancer has led to the identification
of novel drug targets and new ways of treating malignancy with
established drugs. Genetic, genomic and proteomic approaches have identified
biomarkers that may aid in patient selection; novel formulation and
delivery options have led to improved treatment options. Over the past two
decades the taxanes have played a major role in the treatment options of
patients with breast and other cancers; however, there are serious toxicities
associated with taxane treatment and not all patients respond. As a result,
novel strategies for patient selection as well as new formulations of taxanes
have been explored that may both improve anti-tumor activity and reduce
toxicity. However, these improvements in patient care must be appropriately
integrated into widespread clinical practice. The purpose of this educational
symposium is to provide participants with state-of-the-art therapeutic
strategies for use of taxanes in patients with solid malignancies.
The following is list of all 8 sessions
|
Agenda |
|
a. |
Moving towards personalized cancer therapy
David R. Gandara, MD |
|
b. |
Molecular biomarkers of taxane sensitivity and resistance
Rafael Rosell, MD, PhD |
|
c. |
The role of SPARC in enhanced uptake of chemotherapy in tumors
Edith A. Perez, MD |
| d. |
Questions and answers
Faculty and Audience |
|
e. |
Genetic signatures as prognostic indicators for breast cancer
Soonmyung Paik, MD |
|
f. |
Gene expression profiling-based prediction of complete pathologic response to neoadjuvant taxane/FAC chemotherapy in breast cancer
Lajos Pusztai, MD, DPhil, FACP |
|
g. |
The relationship between HER2 expression and response to taxanes
Daniel F. Hayes, MD |
|
h. |
Questions and answers
Faculty and Audience |
|
|
|
Educational Objectives
At the conclusion of all of these enduring materials, you should be able to:
- Describe the benefits of personalizing therapy of breast and lung cancers.
- Explain the role of SPARC as a means of enhancing uptake of certain
taxanes
- Explain how the expression of HER2 can help predict responses to taxanes.
- Understand how genetic signatures can be used as prognostic indicators
for breast cancer.
- Describe how molecular biomarkers can be used as predictors of taxane
sensitivity and resistance to help determine which breast cancers will
derive the most benefit from adjuvant chemotherapy with taxanes.
- Analyze how gene expression profiling-based prediction of complete
response relates to neoadjuvant taxane/FAC chemotherapy in breast cancer.
Target Audience
This educational activity is designed to meet the educational needs of
oncologists and hematologists who have an interest in the clinical use of
taxanes in the treatment of their patients with solid malignancies. There are
no prerequisites or relevant system barriers to this activity.
CME Accreditation & Credit Designation
The Oncology Learning Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Oncology Learning Center designates this educational activity for a maximum of 2 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificate or Certificate of Participation
The relevant section(s) of the Evaluation Form pertaining to the session(s) of the enduring materials you have viewed or listened to, and the Request for Credit Form must be completed and submitted to the Oncology Learning Center following your participation in the enduring material educational activity to obtain CME credit. Physicians and other participants will be able to print their certificates after they complete these Forms.
Disclosure of Conflicts of Interest
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Oncology Learning Center must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an OLC-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. |
|
Faculty Disclosures
It is the policy of The Oncology Learning Center™, Inc. (OLC) to ensure that all of its educational activities and materials are of the highest quality, and are balanced, objective, independent, free of commercial bias, and planned and developed with scientific rigor with strict adherence to all Accreditation Council for Continuing Medical Education (ACCME) rules and policies. The OLC evaluates all content, faculty and faculty disclosures for any potential conflicts of interest. Should any conflicts of interest be identified these conflicts are resolved in advance of the educational activity by independent peer reviewers who are experts in the subjects of the educational activity.
All faculty and OLC staff participating in the content, planning or implementation of an educational CME activity are required to disclose to the audience of the educational activity any relevant financial relationships or interests and to assist in the resolution of any conflict of interest that may arise from the relationship(s) or interest(s). It is also the policy of the OLC to require all faculty presenters to make a meaningful disclosure to the audience of their discussions of unlabeled or FDA unapproved drugs, products, tests or devices. This information will be available as part of the educational activity and related material.
The following faculty and OLC staff have reported real or potential relevant conflicts of interest and these conflicts have been resolved, prior to this educational activity through a peer-review process by two medical oncologists who have had no affiliation with this educational activity other than the peer review process. This is documented on this page immediately following the financial disclosures below.
|
David R. Gandara, MD
Consultant: AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Pfizer
Contracted Research: Abbott, Bristol-Myers Squibb, Lilly
Board of Directors for Response Genetics
I intend to reference unlabeled/unapproved uses of drugs or products in my
presentation.
Rafael Rosell, MD, PhD
I have no real or apparent conflicts of interest to report.
Daniel F. Hayes, MD
Consultant: Pfizer, Predictive Biosciences, Sanofi-Aventis,
Siemens Medical Solutions Diagnostics
Contracted Research: AstraZeneca, GlaxoSmithKline, Novartis, Pfizer,
Wyeth Ayerst/Genentics Institute.
Soonmyung Paik, MD
Receipt of Intellectual Property Rights/Patent Holder: Genomic Health Inc.
Consultant: Genentech
I intend to reference unlabeled/unapproved uses of drugs or products in my
presentation.
Edith A. Perez, MD
I have no real or apparent conflicts of interest to report.
I intend to reference unlabeled/unapproved uses of drugs or products in my
presentation.
Lajos Pusztai, MD, DPhil, FACP
Consultant: Bristol-Myers Squibb, Roche Laboratories, Pfizer
Ownership Interest: Nuvera Biosciences Inc.
|
Faculty Affiliations
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Associate Director for Clinical Research
Director, Thoracic Oncology Program
UC Davis Cancer Center
Sacramento, CA
|
|
Lajos Pusztai , MD, DPhil, FACP
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas
M. D. Anderson Cancer Center
Houston, TX
|
Daniel F. Hayes, MD
Professor, Department of Internal Medicine
Co-Director, Breast Care Center
Clinical Director, Breast Oncology Program
University of Michigan
Comprehensive Cancer Center
Ann Arbor, MI
|
|
Edith A. Perez, MD
Serene M. and Frances C. Durling
Professor of Medicine
Division of Hematology/Oncology
Director, Clinical Investigations
Director, Breast Cancer Program
Chair, Breast Committee for the North Central
Cancer Treatment Group (NCCTG)
Mayo Clinic, Jacksonville, FL
|
Soonmyung Paik, MD
Director, Division of Pathology
National Surgical Adjuvant Breast
and Bowel Project (NSABP)
Pittsburgh, PA
|
|
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
|
|
Peer Review Process of Conflicts of Interest
Drs. Jennifer Ligibel of the Dana Farber Cancer Institute, Boston, MA, and Patrick J. Flynn of US Oncology in Minneapolis, MN have independently peer-reviewed this enduring material educational activity.
Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians’ Desk Reference.
The Oncology Learning Center (OLC) does not recommend the use of any agent outside of the FDA labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the OLC. Please refer to the official FDA prescribing information for each product for discussion of approved indicated, contraindications, and warnings.
Acknowledgement of Supporters
|
